The Downhill Slide: And February Makes Three [View article]
I saw that. The stock moved and came back. Do you have any idea how long the evaluation takes based historically on other Material Transfer agreements...?
*Also a sincere suggestion would be for you to write your own article about nnvc in addition to leaving it on everyone else's comments... There aren't many articles on nnvc.
I would like to find out more information on the company.
Rich
On Mar 02 12:30 PM MarvinMBA wrote:
> Some companies have the potential to be very successfull in spite > of this market downdraft. As an example: > > WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: > NNVC.OB) (the "Company"), reported today that it has signed a Material > Transfer Agreement with a major pharmaceutical company (“Party”). > The Agreement initially entails evaluation of one of the Company’s > nanoviricide drug candidates by an independent consultant chosen > by the Party. This drug candidate has been designed to eradicate > viral infections of the external eye, including those caused by adenovirus > and herpes virus (“HSV”). It is the understanding of the Parties > that, should the testing results be favorable, they will enter into > good faith negotiations for a potential long-term, exclusive, worldwide > licensing agreement for the development and commercialization of > the drug.
The Downhill Slide: And February Makes Three [View article]
*Also a sincere suggestion would be for you to write your own article about nnvc in addition to leaving it on everyone else's comments... There aren't many articles on nnvc.
I would like to find out more information on the company.
Rich
On Mar 02 12:30 PM MarvinMBA wrote:
> Some companies have the potential to be very successfull in spite
> of this market downdraft. As an example:
>
> WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB:
> NNVC.OB) (the "Company"), reported today that it has signed a Material
> Transfer Agreement with a major pharmaceutical company (“Party”).
> The Agreement initially entails evaluation of one of the Company’s
> nanoviricide drug candidates by an independent consultant chosen
> by the Party. This drug candidate has been designed to eradicate
> viral infections of the external eye, including those caused by adenovirus
> and herpes virus (“HSV”). It is the understanding of the Parties
> that, should the testing results be favorable, they will enter into
> good faith negotiations for a potential long-term, exclusive, worldwide
> licensing agreement for the development and commercialization of
> the drug.